Shares slid as investors cashed in gains ahead of Rocket Lab's Q1 2026 earnings report, erasing yesterday's +7.5% surge and raising a pointed question: how long can a company losing money command a nearly $48 billion market cap?
A 30% Rally Left the Stock Priced for Perfection
RKLB climbed more than 25% over the past month , and its valuation sits at a premium 46x forward price-to-sales ratio compared to the sector's 11.64x average — meaning investors are paying roughly four times what they'd pay for a typical aerospace stock relative to expected revenue. This elevated multiple leaves minimal margin for disappointment. Today's -4.4% drop to $80.92 looks like a textbook case of investors locking in profits before the after-hours earnings call.
Wall Street Expected Improvement, Not a Miracle
Analysts expected a Q1 loss of $0.07 per share, improving from a $0.12 loss a year ago, with revenue projected to surge more than 50% year over year to roughly $189.65 million.
The company had guided Q1 revenue to $185M–$200M with GAAP gross margins of 34%–36% , lower than the prior quarter's 38% due to business mix. That margin dip signals Rocket Lab is still spending heavily to grow, not yet converting revenue gains into bottom-line profits.
The Neutron Rocket Is the Real Bet — and It Hit a Snag
A Neutron Stage 1 tank ruptured during qualification testing due to a manufacturing defect. The company shifted production to automated methods and now targets a first launch in Q4 2026.
The 43-meter partially reusable rocket is designed for satellite launches and cargo missions and could position Rocket Lab as a direct competitor to SpaceX's Falcon 9. Any further delays would undercut the growth narrative propping up the stock's rich valuation.
Insiders Were Selling Into the Strength
CEO Peter Beck sold 18,857 shares in early March at $69.59, while CFO Adam Spice sold 62,744 shares worth roughly $4.37 million. Company insiders offloaded $16.49 million in stock over the prior 90 days. That's not unusual for a high-growth company, but it adds another layer of caution for shareholders betting on a stock that has yet to turn a profit against a record backlog of ~$1.85 billion . The earnings call at 5 p.m. ET will determine whether this dip is a buying opportunity — or the start of a longer reality check.